The influence of the anticonvulsive drug phenytoin on the periodontal tissues during orthodontic tooth movement in the rat was studied. The experimental and the control group each consisted of 10 Sprague-Dawley rats. The test group was injected daily with phenytoin during the experimental period of 6 weeks. A fixed appliance for expansion was applied on the first molars in both groups after 2 weeks (day 15). At the end of the experiment (day 42), radiographic measurements revealed less tooth movement in the phenytoin-treated rats. Compared to the control group, significant histologic changes in the periodontal tissues such as increased density of fibroblasts, decreased number of osteoclasts in contact with alveolar bone wall of the pressure side and deeper layer of non-mineralized osteoid on the tension side were observed in the phenytoin group.
Get full access to this article
View all access options for this article.
References
1.
ArielM., EilamY., JablonskaM. and GrossowiczN. (1982) Effects of phenytoin on folic acid uptake in isolated intestinal epithelial cells, Journal of Pharmacology and Experimental Therapeutics, 223, 224–226.
2.
BrownR. S., BeaverW. T. and BottomleyW. K. (1996) On the mechanism of drug-induced gingival hyperplasia, Journal of Oral Pathology and Medicine, 20, 201–209.
3.
BrudvikP. and RyghP. (1993) Non-clast cells start orthodontic root resorption in the periphery of hyalinized zones, European Journal of Orthodontics, 15, 467–480.
4.
BrudvikP. and RyghP. (1994) Root resorption beneath the main hyalinized zone, European Journal of Orthodontics, 16, 249–263.
5.
DahllöfG., PreberH., EliassonS., RydénH., KarstenJ. and ModéerT. (1992) Periodontal condition of epileptic adults on long-term medication with phenytoin or carbamazepine, Epilepsia, 34, 960–964.
6.
DavidovitchZ., NicolayO., NganP. W. and ShanfeldJ., (1988) Neurotransmitters, cytokines and the control of alveolar bone remodeling in orthodontics, Dental Clinics of North America, 32, 411–435.
7.
DentC. E., RichensA., RoweD. J. F. and StampT. C. B. (1970) Osteomalacia with long-term anticonvulsant therapy in epilepsy, British Medical Journal, 4, 69–72.
8.
DinarelloC. A., MarnoyS. O. and RosenwasserL. J. (1983) Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin-1, Journal of Immunology, 130, 890–895.
9.
GinigerM. S., NortonL., SousaS., LorenzoJ. A. and BronnerF. (1991) A human periodontal ligament fibroblast clone releases a bone resorption inhibition factor in vitroiJournal of Dental Research, 70, 99–101.
10.
HahnT. J., HendinB. A., ScharpC. R.HaddadJ. G. (1972) Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol level in adults, New England Journal of Medicine, 287, 899–904.
11.
HassellT. (1981) Epilepsy and the Oral Manifestations of Phenytoin Therapy, Karger, Basel, Switzerland.
12.
HassellT., PageR., NarayananA. and CooperC. (1976) Diphenylhydantoin gingival hyperplasia: drug-induced abnormality of connective tissue, Proceedings of the National Academy of Science, 73, 2909–2912.
13.
HassellT., PageR. and LindheJ. (1978) Histologic evidence for impaired growth control in diphenylhydantoin gingival overgrowth in man, Archives of Oral Biology, 23, 381–384.
14.
HellsingE. and HammarströmL. (1991) The effects of pregnancy and fluoride on orthodontic tooth movements in rats, European Journal of Orthodontics, 13, 223–230.
15.
HellsingE. and HammarströmL (1996) The hyaline zone and associated root surface changes in experimental orthodontics in rats: a light and scanning electron microscope study, European Journal of Orthodontics, 18, 11–18.
16.
HolmbergB., KroneviT. and EknerA. (1986) Subchronic investigation of ethyl alcohol: A test for lowest effective dose (LED) to be used in a long-term bioassay for carcinogenicity, Arbete och Hälsa, The National Board of Occupational Safety and Health, Solna, Sweden, 14, 1–29.
17.
KattanK. (1970) Calvarial thickening after Dilantin medication, American Journal of Roentgenology Radium Therapy Nuclear Medicine, 110, 102–105.
18.
KimballO. P. (1939) Treatment of epilepsy with sodium diphenyl hydantoinate, Journal of the American Medical Association, 112, 1244–1245.
19.
LauKH. W., NakadeO., TaylorA. K., HouchinK. and BaylinkD. J. (1994) Low dose phenytoin is osteogenic for the human species in vitro and in vivo, Journal of Bone and Mineral Research, 9, 152.
20.
LefebvreE. B., HainingR. G. and LabbéeR. F. (1972) Coarse facies, calvarial thickening and hyperphosphatasia associated with long-term anticonvulsant therapy, New England Journal of Medicine, 286, 1301–1302.
21.
LivingstonS., BermanW. and PauliL. L. (1973) Anticonvulsant drugs and vitamin D metabolism, Journal of the American Medical Association, 224, 1634–1635.
22.
MelsenB., MelsenF. and MosekildeL. (1976) Bone changes of importance in the orthodontic patient with epilepsy, Transactions of the European Orthodontic Society, 227–233.
23.
MerrittH. H. and PutnamT. J. (1938) Sodium diphenyl hydantoinate in treatment of convulsive disorders, Journal of the American Medical Association, 111, 1068–1073.
24.
MidgettR. J., ShayeR. and FrugeJ. F. (1981) The effect of altered bone metabolism on orthodontic tooth movement, American Journal of Orthodontics, 80, 256–62.
25.
ModéerT. and DahllöfG. (1987) Development of phenytoin-induced gingival overgrowth in noninstitutionalized epileptic children subjected to different plaque control programs, Acta Odontologica Scandinavica, 45, 81–85.
26.
ModéerT. and DahllöfG. (1987) Oral health in non-institutionalized epileptic children with special reference to phenytoin medication, Community Dental Oral Epidemiology, 14, 165–168.
27.
NakadeO., BaylinkD. J. and LauK-H. W. (1995) Phenytoin at micromolar concentrations is an osteogenic agent for human mandible derived bone cells in vitro, Journal of Dental Research, 74, 331–337.
28.
OhtaT., WergedalJ. E., GruberH. E., BaylinkD. J. and LauKH. W. (1995) Low dose phenytoin is an osteogenic agent in the rat, Calcified Tissue International, 56, 42–48.
29.
RichensA. and RoweD. J. F. (1970) Disturbance of calcium metabolism by anticonvulsant drugs, British Medical Journal, 4, 73–76.
30.
RobertsW. E. and JeeW. S. S. (1974) Cell kinetics of orthodontically-stimulated and non-stimulated periodontal ligament in the rat, Archives of Oral Biology, 19, 17–21.
31.
SaitoS., NganP., SaitoM., KimK., LaneseR., ShanfeldJ. and DavidovitchZ. (1990) Effects of cytokines on prostaglandin E and cAMP levels in human periodontal ligament fibroblasts in vitro, Archives of Oral Biology, 35, 387–395.
32.
SaitoM., SaitoS., NganP., ShanfeldJ. and DavidovitchZ. (1991) Interleukin-1 beta and prostaglandin E are involved in the response of peridontal cells to mechanical stress in vivo and in vitro, American Journal of Orthodontics, 99, 226–40.
33.
TurnerR. T., GreeneV. S. and BellN. H. (1987) Demonstration that ethanol inhibits bone matrix synthesis and mineralisation in the rat, Journal of Bone and Mineral Research, 2, 61–66.
34.
TurnerR. T., AloiaR. C., SegelL. D., HannonK. S. and BellN. H. (1988) Chronic alcohol treatment results in disturbed vitamin D metabolism and skeletal abnormalities in rats, Alcoholism: Clinical and Experimental Research, 12, 159–162.
35.
VasC. J. and ParsonageM. J. (1967) Treatment of intractable temporal lobe epilepsy with pheneturide, Acta Neurological Scandinavica, 43, 580–586.
36.
VogelR.I. (1977) Gingival hyperplasia and folic acid deficiency from anticonvulsive drug therapy: a theoretical relationship, Journal of Theoretical Biology, 67, 269–278.
37.
WilliamsS., MelsenB., AgerbaekN. and AsboeV. (1982) The orthodontic treatment of malocclusion in patients with previous periodontal disease, British Journal of Orthodontics, 9, 178–184.
38.
WrightJ. A. (1965) Trinuride in the treatment of major epilepsy, Epilepsia, 6, 67–74.
